Treatment and management of lipid disorders in the elderly

Mature Medicine Canada

Volumn 3, Issue 4, 2000, Pages 148-152

  Blumberger, D ^a   To, T B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aged; Cardiovascular disease; Dyslipidemia; HMG CoA reductase inhibitors; Statins

Indexed keywords

ATORVASTATIN; BILE ACID; CERIVASTATIN; CYTOCHROME P450; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; CORONARY RISK; DOSE RESPONSE; DYSLIPIDEMIA; ELDERLY CARE; HALF LIFE TIME; HUMAN; HUMAN TISSUE; LIFESTYLE; POLYPHARMACY; PRESCRIPTION; REVIEW;

EID: 0033663957     PISSN: 14805537     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Vital and Health Statistics
2. Cardiovascular disease prevention in the elderly
3. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study
4. Plasma cholesterol concentration and mortality: The Whitehall Study
5. High density lipoprotein cholesterol and cardiovascular disease
6. Triglyceride and cholesterol rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
7. Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience)
8. Secondary causes of dyslipidemia
9. Cholesterol metabolism and aging
10. Dyslipoproteinemia in the elderly: Should it be treated?
11. Aging and total cholesterol levels: Cohort, period and survivorship effects
12. Cholesterol and coronary heart disease: The importance of patient-specific attributable risk
13. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons
14. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and American College of Cardiology
15. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary
16. Relationship between physical acitivity and HDL cholesterol in healthy older men and women: A cross-sectional and exercise intervention study
17. Effects of National Cholesterol Education Program Step 2 Diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects
18. Women and men with hypercholesterolemia respond similarly to an American Heart Association Step 1 Diet
19. Cholesterol-lowering diets: A review of the evidence
20. Nutrition and therapeutics: Where we are and where we should be going
21. Managing dyslipidemia in older adults
22. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study
23. Drug treatment of lipid disorders
24. Lipid-lowering drugs in the management of hyperlipidemia
25. HMG-CoA reductase inhibitors: A look back and a look ahead
26. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
27. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range
28. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol values
29. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of the AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
30. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). PROSPER Study Group
31. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
32. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid
33. Chylomicronemia syndrome: Interaction of genetic and acquired hypertriglyceridemia
34. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
35. The second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
36. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
37. Total cholesterol and risk of mortality in the oldest old
38. Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias